NASDAQ$EHTH

eHealth Inc · Q4 2022 earnings

Q4 2022 earnings · · Investor relations

Briefing

eHealth reported strong FY 2022 results and Q4 2022 net income, with significant improvements in operating efficiency and adjusted EBITDA.

eHealth, Inc. announced its Q4 and FY 2022 financial results, outperforming the high end of its FY 2022 guidance. The company reported a Q4 net income of $20.7 million, a significant improvement from the previous year's net loss, and a 76% increase in adjusted EBITDA. These results were driven by operational efficiencies and cost savings.

  • Q4 2022 net income was $20.7 million, compared to a net loss of $32.2 million in Q4 2021.
  • Adjusted EBITDA improved 76% compared to Q4 2021, with the adjusted EBITDA margin more-than-doubling from 12% to 25%.
  • Telephonic conversion rate increased by 25% in Q4 2022.
  • Medicare Advantage LTV increased to $1,033 from $1,017 in Q4 2021, a 2% improvement.

Headline financials

Total Revenue

$196M

Previous: $244M-19.4%
EPS (adj)

$1.14

Previous: $0.49+132.7%
Capital Expenditures

$22K

Previous: $311K-92.9%
Free Cash Flow

-$18.6M

Previous: -$103M+81.9%
Net Income

$20.7M

Previous: -$32.2M+164.3%
Operating Income

$30.7M

Previous: -$33.6M+191.4%
Gross Profit

$195M

Previous: $243M-19.5%
Cash & Equivalents

$144M

Previous: $81.9M+76.3%
Total Assets

$1.11B

Previous: $1.15B-3.2%
Stock-Based Comp

$4.38M

Previous: $7.98M-45.1%

Revenue & EPS history

eHealth · Revenue · Quarterly

$196M

Q4 2022-19.4%vs Q4 2021
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Revenue by segment

eHealth · $64.7M total across 2 segments · Q3 2023

  • Medicare
    $55.5M+23.0%
  • Employer and Individual
    $9.2M

Forward guidance

eHealth provided guidance for the full year ending December 31, 2023, expecting total revenue in the range of $420 million to $440 million and adjusted EBITDA in the range of $(15) million to $5 million.

Tailwinds

  • Total revenue is expected to be in the range of $420 million to $440 million.
  • Expects return to revenue growth at 6%.
  • Achieving GAAP net loss of roughly $45.0 million.
  • Year-over-year improvement in adjusted EBITDA of roughly $37.0 million.
  • Expect to have sufficient liquidity to support our business needs and objectives in FY 2023.

Headwinds

  • GAAP net loss is expected to be in the range of $55 million to $35 million.
  • Adjusted EBITDA is expected to be in the range of $(15) million to $5 million.
  • Operating cash flow is expected to be in the range of $(30) million to $(15) million.
  • Lower Medicare approved enrollments in FY 2022.
  • Midpoint of 2023 annual guidance implies return to revenue growth at 6% while achieving GAAP net loss of roughly $45.0 million and year-over-year improvement in adjusted EBITDA of roughly $37.0 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2022

Historical avgQ4 2022

-1.0%

Avg return

Earnings day

-1.1%

Avg return

5 days after

+0.6%

Avg return

30 days after

45%

29 / 65 earnings

Positive

+25.2%

Q3 2022

Best reaction

-34.3%

Q2 2014

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+1.5%-7.1%-12.7%
Q4 2025-30.7%-17.5%-32.3%
Q3 2025-21.8%-16.2%-22.9%
Q1 2025+23.2%+19.2%-8.1%
Q4 2024+3.3%-5.7%-28.2%
Q3 2024+9.2%+3.5%+12.2%
Q2 2024-12.8%-7.7%-18.8%
Q1 2024+12.4%+8.2%+9.4%
Q4 2023-8.2%-7.1%-14.6%
Q3 2023-8.5%-11.7%+2.1%
Q2 2023-0.1%-1.1%-14.2%
Q1 2023+15.1%+8.2%+49.1%
Q4 2022-8.4%+2.5%+5.4%
Q3 2022+25.2%+27.8%+47.4%
Q2 2022-2.7%+16.8%-32.2%
Q1 2022+22.5%+31.1%+31.1%
Q4 2021-16.7%-25.5%-20.1%
Q3 2021-25.8%-30.7%-35.2%
Q2 2021-5.9%-9.3%-28.6%
Q1 2021-0.7%-5.2%-8.4%
Q4 2020+5.9%+6.6%+19.4%
Q3 2020-6.8%-8.2%-8.7%
Q2 2020-31.1%-36.9%-40.3%
Q1 2020-8.1%-7.1%+12.4%
Q4 2019-0.6%-13.7%-22.3%
Q3 2019+0.2%+10.8%+39.3%
Q2 2019+24.8%+21.5%+10.5%
Q1 2019+3.7%-2.0%+4.3%
Q4 2018-3.6%-7.2%-4.9%
Q3 2018+13.2%+15.2%+23.0%
Q2 2018-3.6%-1.2%+24.6%
Q1 2018+17.3%+21.6%+31.9%
Q4 2017-16.2%-4.1%-12.2%
Q3 2017+7.0%+15.3%+3.5%
Q2 2017-5.3%-8.3%+23.3%
Q1 2017+23.2%+39.6%+59.9%
Q4 2016+8.9%+6.3%+2.5%
Q3 2016-31.8%-30.2%-5.6%
Q2 2016-29.4%-32.2%-18.6%
Q1 2016+23.2%
Q4 2015+0.7%
Q3 2015-4.2%
Q2 2015+21.4%
Q1 2015+13.5%
Q4 2014-3.6%
Q3 2014+15.4%
Q2 2014-34.3%
Q1 2014-12.3%
Q4 2013-8.5%
Q3 2013+9.6%
Q2 2013-1.8%
Q1 2013+7.3%
Q4 2012-22.8%
Q3 2012+9.5%
Q4 2011-1.1%
Q2 2012+9.7%
Q1 2011+1.0%
Q1 2012+0.6%
Q4 2009-2.5%
Q3 2010-3.1%
Q3 2011-3.1%
Q4 2010-7.0%
Q2 2011-7.0%
Q2 2010-7.0%
Q1 2010+2.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro